Quick Answer
Organon & Co. reported Net Income Loss of $187.00 million for the year ending 2025.
- Organon & Co. showed a decrease of -78.4% in Net Income Loss from 2024 to 2025.
- This data is from Organon & Co.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $703.00 million | Q2 2020: $542.00 million | Q3 2020: $547.00 million | Q1 2021: $399.00 million | Q2 2021: $427.00 million | Q3 2021: $323.00 million | Q1 2022: $348.00 million | Q2 2022: $234.00 million | Q3 2022: $227.00 million | Q1 2023: $177.00 million | Q2 2023: $242.00 million | Q3 2023: $58.00 million | Q1 2024: $201.00 million | Q2 2024: $195.00 million | Q3 2024: $359.00 million | Q1 2025: $87.00 million | Q2 2025: $145.00 million | Q3 2025: $160.00 million.
- Over the full 7 years of available data (2019 to 2025), Organon & Co.'s Net Income Loss has declined by 94.2%.
- Historical annual values: Fiscal year 2025: $187.00 million | Fiscal year 2024: $864.00 million | Fiscal year 2023: $1.02 billion | Fiscal year 2022: $917.00 million | Fiscal year 2021: $1.35 billion | Fiscal year 2020: $2.16 billion | Fiscal year 2019: $3.22 billion.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: